Obese asthma phenotypes display distinct plasma biomarker profiles
- PMID: 36973952
- PMCID: PMC10032201
- DOI: 10.1002/clt2.12238
Obese asthma phenotypes display distinct plasma biomarker profiles
Abstract
Background: Obese asthma is a complex phenotype and further characterization of the pathophysiology is needed. This study aimed to explore inflammation-related plasma biomarkers in lean and overweight/obese asthmatics.
Methods: We elucidated levels of inflammation-related plasma proteins in obese asthma phenotypes in the population-based cohort BAMSE (Swedish: Children, Allergy, Milieu, Stockholm, Epidemiology) using data from 2069 24-26-year-olds. Subjects were divided into lean asthma (n = 166), lean controls (n = 1440), overweight/obese asthma (n = 73) and overweight/obese controls (n = 390). Protein levels (n = 92) were analysed using the Olink Proseek Multiplex Inflammation panel.
Results: Of the 92 included proteins, 41 were associated with lean and/or overweight/obese asthma. The majority of proteins associated with overweight/obese asthma also associated with overweight/obesity among non-asthmatics. Beta-nerve growth factor (BetaNGF), interleukin 10 (IL-10), and matrix metalloproteinase 10 (MMP10) were associated only with lean asthma while C-C motif chemokine 20 (CCL20), fibroblast growth factor 19 (FGF19), interleukin 5 (IL-5), leukemia inhibitory factor (LIF), tumor necrosis factor ligand superfamily member 9 (TNFRSF9), and urokinase-type plasminogen activator (uPA) were associated only with overweight/obese asthma. Overweight/obesity modified the association between asthma and 3 of the proteins: fibroblast growth factor 21 (FGF21), interleukin 4 (IL-4), and urokinase-type plasminogen activator (uPA). In the overweight/obese group, interleukin-6 (IL-6) was associated with non-allergic asthma but not allergic asthma.
Conclusion: These data indicate distinct plasma protein phenotypes in lean and overweight/obese asthmatics which, in turn, can impact upon therapeutic approaches.
Keywords: asthma; body mass index; inflammation; obesity; plasma biomarker.
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Conflict of interest statement
EM reports lecture, consulting or advisory boards fees from AstraZeneca, Chiesi, Novartis and Sanofi outside the submitted work. SK reports lecture or advisory boards fees from Novartis and AstraZeneca outside the submitted work. MvH has received lecture fee from Thermo Fisher Scientific outside the submitted work. The other authors declare no conflicts of interest.
Figures


Similar articles
-
Innate immunity in obese asthmatic allergic and nonallergic adults.Egypt J Immunol. 2009;16(2):1-8. Egypt J Immunol. 2009. PMID: 22059348
-
Role of adiponectin, resistin and monocyte chemo-attractant protein-1 in overweight/obese asthma phenotype in children.BMC Pediatr. 2023 May 6;23(1):226. doi: 10.1186/s12887-023-04046-6. BMC Pediatr. 2023. PMID: 37149591 Free PMC article.
-
Systemic inflammation mediates the detrimental effects of obesity on asthma control.Allergy Asthma Proc. 2018 Jan 2;39(1):43-50. doi: 10.2500/aap.2018.39.4096. Allergy Asthma Proc. 2018. PMID: 29279059
-
IL-17 protein levels in both induced sputum and plasma are increased in stable but not acute asthma individuals with obesity.Respir Med. 2016 Dec;121:48-58. doi: 10.1016/j.rmed.2016.10.018. Epub 2016 Oct 28. Respir Med. 2016. PMID: 27888992
-
Mechanistic Basis for Obesity-related Increases in Ozone-induced Airway Hyperresponsiveness in Mice.Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S357-S362. doi: 10.1513/AnnalsATS.201702-140AW. Ann Am Thorac Soc. 2017. PMID: 29161088 Free PMC article. Review.
Cited by
-
Genomics of Treatable Traits in Asthma.Genes (Basel). 2023 Sep 20;14(9):1824. doi: 10.3390/genes14091824. Genes (Basel). 2023. PMID: 37761964 Free PMC article. Review.
-
Impact of obesity on airway remodeling in asthma: pathophysiological insights and clinical implications.Front Allergy. 2024 Mar 18;5:1365801. doi: 10.3389/falgy.2024.1365801. eCollection 2024. Front Allergy. 2024. PMID: 38562155 Free PMC article. Review.
-
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.Respir Res. 2023 Dec 6;24(1):305. doi: 10.1186/s12931-023-02620-1. Respir Res. 2023. PMID: 38057814 Free PMC article.
-
Improved Air Quality and Asthma Incidence from School Age to Young Adulthood: A Population-based Prospective Cohort Study.Ann Am Thorac Soc. 2024 Oct;21(10):1432-1440. doi: 10.1513/AnnalsATS.202402-200OC. Ann Am Thorac Soc. 2024. PMID: 38959417 Free PMC article.
-
Can Biomarkers Correctly Predict Ventilator-associated Pneumonia in Patients Treated With Targeted Temperature Management After Cardiac Arrest? An Exploratory Study of the Multicenter Randomized Antibiotic (ANTHARTIC) Study.Crit Care Explor. 2024 Jul 1;6(7):e1104. doi: 10.1097/CCE.0000000000001104. eCollection 2024 Jul. Crit Care Explor. 2024. PMID: 38957212 Free PMC article. Clinical Trial.
References
Grants and funding
- Region Stockholm, ALF project, Clinical postdoctoral appointment (SK), and database maintenance
- Hjärt-Lungfonden
- European Academy of Allergy and Clinical Immunology, Medium-Term Research Fellowship (NHP)
- Thermo Fisher Scientific, reagents for the allergen-specific IgE analyses
- Insamlingsstiftelsen Cancer- och Allergifonden
- 757919/H2020 European Research Council
- LTRF202101-00861/European Respiratory Society (NHP)
- 2016-01646/Svenska Forskningsrådet Formas
- 2017-00526/Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- 2016-03086/Vetenskapsrådet
- 2018-02524/Vetenskapsrådet
- 2019-01060/Vetenskapsrådet
- 2020-02170/Vetenskapsrådet
- Astma- och Allergiförbundet
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous